The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin [PDF]
Drugs, 2021 The epidemiology of invasive fungal infections is changing, with new populations at risk and the emergence of resistance caused by the selective pressure from increased usage of antifungal agents in prophylaxis, empiric therapy, and agriculture.
M. Hoenigl +11 more
semanticscholar +5 more sources
Treatment of Recurrent Vulvovaginal Candidiasis With Ibrexafungerp
Journal of Investigative Medicine High Impact Case Reports, 2022 Recurrent vulvovaginal candidiasis is a common disorder which causes significant morbidity among women worldwide, and treatment options are limited.
Leah M. Grant MD, Robert Orenstein DO
doaj +3 more sources
Novel Therapeutic Approaches to Invasive Candidiasis: Considerations for the Clinician [PDF]
Infection and Drug Resistance, 2023 Frederic Lamoth1,2 1Infectious Diseases Service, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland; 2Institute of Microbiology, Department of Laboratory Medicine and Pathology, Lausanne University ...
Lamoth F
doaj +3 more sources
EUCAST Ibrexafungerp MICs and Wild-Type Upper Limits for Contemporary Danish Yeast Isolates [PDF]
Journal of Fungi, 2022 Ibrexafungerp is a novel triterpenoid antifungal that inhibits glucan synthase and thus fungal cell wall synthesis. We examined the in vitro activity against contemporary clinical yeast, investigated inter-laboratory and intra-laboratory variability ...
Karin M. Jørgensen +3 more
doaj +4 more sources
Antibiotics, 2020 Candida auris is an emerging multidrug-resistant fungal pathogen reported worldwide. Infections due to C. auris are usually nosocomial and associated with high rates of fluconazole resistance and mortality.
Mahmoud Ghannoum +11 more
doaj +2 more sources
P-1096. Activity of Ibrexafungerp and Comparator Antifungals Tested against Candida and Aspergillus Isolates Collected from Invasive Infections in a Global Surveillance Program in 2023 [PDF]
Open Forum Infect DisBackground Ibrexafungerp (IBX) is a novel triterpenoid antifungal agent that was approved by the U.S. FDA for the treatment of vulvovaginal candidiasis (VVC) in 2021. Further studies are ongoing to assess the efficacy of IBX for the treatment of invasive
Marisa L Winkler +5 more
europepmc +2 more sources
Journal of Fungi, 2021 Ibrexafungerp is a new orally-available 1,3-β-D-glucan synthesis inhibitor in clinical development. Its in vitro activity and that of amphotericin B, voriconazole, and micafungin were evaluated against a collection of 168 clinical isolates of Aspergillus
Olga Rivero-Menendez +3 more
doaj +2 more sources
Pharmacokinetics and Pharmacodynamics of Ibrexafungerp [PDF]
Drugs in R&D, 2021 On 2 June, 2021, the US Food and Drug Administration approved ibrexafungerp (formerly MK-3118 and SCY-078) for the treatment of vulvovaginal candidiasis, also known as vaginal yeast infection.
M. McCarthy
semanticscholar +3 more sources
Antibiofilm activity of manogepix, ibrexafungerp, amphotericin B, rezafungin, and caspofungin against Candida spp. biofilms of reference and clinical strains. [PDF]
Antimicrob Agents ChemotherThis study comprehensively assessed the activity of manogepix (MNGX), ibrexafungerp (IBF), amphotericin B (AMB), rezafungin (RZF), and caspofungin (CAS) against planktonic cells and mature biofilms of Candida spp.—reference and clinical strains using the
Ceballos-Garzon A +5 more
europepmc +2 more sources
Our current clinical understanding of Candida biofilms: where are we two decades on? [PDF]
APMIS, Volume 131, Issue 11, Page 636-653, November 2023., 2023 Clinically we have been aware of the concept of Candida biofilms for many decades, though perhaps without the formal designation. Just over 20 years ago the subject emerged on the back of progress made from the bacterial biofilms, and academic progress ...
Borghi, Elisa +5 more
core +4 more sources